Refine
Document Type
- Doctoral Thesis (4)
Language
- English (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- Vaccine (4) (remove)
Immunogenicity and protectivity of surface-localized lipoproteins of Streptococcus pneumoniae
(2019)
Steptococcus pneumoniae (pneumococcus) represents a common colonizer of the human upper respiratory tract (URT). However, under certain conditions, for example following viral infections, or in indiciduals with a weakened immune system, including young children, elderly and immunocompromised persons, it can cause a wide range of life-threatening diseases, such as pneumonia, meningitis or sepsis. Based on the polysaccharide capsule that surrounds the bacterium, pneumococci are classified into so far 98 different serotypes. Prevention of S. pneumoniae infections was achieved by the development of pneumococcal polysaccharide-based (PPSV) vaccines. However, these vaccines have important limitations, including high manufacturing costs and restricted serotype coverage facilitating replacement by non-vaccine serotypes. Aiming for the development of a serotype-independent vaccine, the potential of surface-exposed and highly conserved pneumococcal lipoproteins was evaluated for being targeted as a future protein-based vaccine. Therefore, selected lipoproteins were examined i) for their surface abundance and accessibility, ii) for their presence in clinically relevant S. pneumoniae strains, and iii) for their immunogenicity. Finally, based on these initial screenings, the most promising candidates were selected to analyze their protective efficacy in a moude model of colonization. DacB and PnrA were identified as highly abundant lipoproteins on the pneumococcal surface. They showed to be immunogenic both during natural infection using convalescent patient sera and when given to mice as a subunit vaccine formulation. Following intranasal immunization and challenge of mice with two heterologous S. pneumoniae strains, both proteins reduced the pneumococcal load in the nasopharynx. The protection correlated with increased production of IL-17A indicative for a Th17-mediated immunity, which is strongly suggested to play a critical role in preventing pneumococcal colonization and infection. Lipoproteins are triggering innate receptors on antigen-presenting cells, thereby linking innate with adaptive immune responses. Therefore, lipidated proteins were evaluated for their potential to be used as an adjuvant for vaccination. Lipidation clearly enhanced humoral immune responses to DacB and PnrA without the need of an additional adjuvant. However, an additional adjuvant was required to confer protection against pneumococcal colonization. In conclusion, Lipoproteins are interesting candidates for future protein-based vaccine strategies because they are highly conserved, abundant and immunogenic. PnrA and DacB were identified as potential candidates, since they induced protection against pneumococcal colonization, which in turn may lead to a decline in infections and transmission.
To enable control of African swine fever (ASF) in Eastern and Southern Africa, prototype live vaccine candidates were generated by targeted gene deletions from a Kenyan genotype IX ASF virus (ASFV). It was attempted to delete known nonessential genes involved in virulence (encoding TK, dUTPase, CD2v, 9GL), possibly essential genes (p12, pA104R, ribonucleotide reductase), and genes with widely unknown functions (pK145R). Isolation of the desired virus recombinants by plaque assays or limiting dilutions on a wild boar lung cell line (WSL-HP) was facilitated by substitutive reporter gene insertions encoding fluorescent proteins (GFP, DsRed), or the human membrane protein CD4. The latter protein permitted enrichment of recombinant virus particles by magnetic activated cell sorting (MACS). The isolated ASFV recombinants were characterized by PCR and sequencing of the mutated genome parts, and replication kinetics and virus spread in cell culture were investigated. Deletion of TK, CD2v, or pK145R had no detectable effect on in vitro growth of ASFV Kenya. Interestingly, virus mutants lacking the DNA binding protein pA104R which has been considered to be essential for DNA replication, also exhibited almost wild type-like growth properties.
In contrast, ASFV mutants lacking ribonucleotide reductase or p12 could not be purified to homogeneity on WSL-HP cells, indicating these proteins are essential for virus replication in cell culture. Therefore, trans-complementing cells lines stably expressing ASFV p12 have been prepared which can now be used for mutant virus purification. If this approach is successful the resulting defective mutant ASFV Kenya-p12 might be suitable as a safe “disabled in second cycle” (DISC) live vaccine in swine.
In a novel approach to improve reverse genetics of ASFV the CRISPR/Cas9 cell line WSL-gRp30 (Hübner et al., 2018a) was co-transfected with genomic DNA of ASFV-KenyaCD2vDsRed, sgRNA plasmids targeting K145R or 9GL, and GFP-expressing recombination plasmids for homology-directed repair. For booting up of the noninfectious virus genome the cells were infected with phylogenetically distant helper virus (genotype II ASFV Armenia, 84% identity) which was selectively inhibited on the used cell line. The desired double-fluorescent double-deletion mutants could be isolated after few plaque purification steps on selective WSL-gRp30 cells. Next generation sequence (NGS) analyses of reconstituted ASFV Kenya genomes showed that no unwanted recombination with the helper virus occurred, indicating that the method might be also suitable for booting of synthetic ASFV genomes cloned and mutagenized in E. coli or yeast.
The modified CRISPR/Cas9 system of S. pyogenes might be also usable for generation of ASFV resistant pigs. To evaluate this alternative control measure WSL cell clones stably expressing Cas9 nuclease and single or multiple sgRNAs against essential ASFV proteins were prepared and tested for their susceptibility to infection. Strain specific sgRNAs targeting the p30 gene of ASFV Kenya or Armenia selectively inhibited the respective viruses, and a p12 gene-specific sgRNA abrogated replication of both genotypes almost completely. Interestingly, coexpression of four ASFV-specific sgRNAs did not enhance virus inhibition, but might help to reduce the frequency of escape mutants which were occasionally isolated from the single sgRNA-expressing cells, and exhibited silent base substitutions or in-frame deletions within the target genes. First attempts to express the in vitro tested CRISPR/Cas9 constructs in transgenic pigs are in progress.
CRISPR/Cas9 supported rescue of a defective BAC clone of pseudorabies virus (PrV) vaccine strain Bartha (Hübner et al., 2018b) was used to develop putative vectored vaccines against ASFV. In the present study expression cassettes for the codon-optimized p12 and p54 genes of ASFV were successfully inserted into the PrV genome. The insertions did not significantly affect PrV recombination in cell culture, and the transgenes were expressed at similar levels as in ASFV-infected cells. It has to be tested whether coinfection with vector constructs for these and other immunogenic ASFV proteins is able to protect pigs against a lethal challenge.
For characterization of the generated ASFV mutants and PrV vector constructs, monospecific antisera against several ASFV gene products (p11.5, p12, p54, pK145R, p285L) were prepared by immunization of rabbits with bacterial GST fusion proteins. The anti-p12 serum showed only weak and strain-specific reactions with the ASFV Kenya protein, but was nevertheless useful for identification of p12-expressing PrV recombinants and WSL cell lines. All other sera showed satisfying reactions in Western blot and mostly immunofluorescence analyses, and allowed i.a. precise localization of the pK145R and p285L proteins in ASFV-infected cells and virions (Hübner et al., 2019).
Gram-negative bacteria are known to naturally produce outer membrane vesicles (OMVs), which are closed nanoparticles (10 to 450 nm) containing virulence factors and pathogen associated molecular patterns (PAMPs). For over 20 years, OMVs of Neisseria meningitidis (N. meningitidis), in combination with three purified outer membrane proteins, have been successfully used as parts of human vaccines which illustrates the safety and potential of OMV based vaccines. So far only little is known about the OMVs of fish pathogenic bacteria. The production of OMVs has been described for the fish pathogenic gram-negative bacterium Aeromonas salmonicida (A. salmonicida) which is the causative agent of furunculosis resulting in high morbidity and mortality of salmonid fish. The immunostimulatory potential of OMVs derived from A. salmonicida as well as the possibility of establishing an oral vaccine model in Oncorhynchus mykiss (O.mykiss) (Rainbow trout) has been investigated in this study by conducting in vitro and in vivo experiments. Innate immune cells such as macrophages are one of the first cells to respond to pathogens once they breach the skin barrier, therefore the monocyte/macrophage cell line RTS-11 as well as leukocytes from the head kidney, consisting of a high percentage of phagocytic cells have been investigated. Additionally, leukocytes isolated from the peritoneal cavity as the main target for injectable vaccines have been studied in the in vitro experiments. These experiments indicate that OMVs derived from A. salmonicida are recognized by the monocyte/macrophage cell line RTS-11 as well as by leukocytes from the head kidney resulting in significant changes of the mRNA expression pattern of early inflammatory markers (IL-1β, IL-6, IL-8, IL-10, TGFβ). Having used the established peritoneal inflammation model of rainbow trout it could be shown that intraperitoneal (i.p.) vaccination of rainbow trout with OMVs results in a similar local immune response, especially in the recruitment of myeloid cells, compared to the injection of inactivated bacteria. The systemic cellular immune response differed between the two vaccine groups, even though a similar humoral immune response could be observed. Interestingly, i.p.vaccination with 10 µg of OMVs resulted in similar antibody titers as observed for fish, that were i.p. vaccinated with 108 CFU of inactivated A. salmonicida. The similar antibody titers after vaccination with OMVs might be explained by a stronger activation of CD8- T cells (likely CD4+ T cells) in the head kidney as well as in the blood in the OMV vaccinated group alone, which might result in an increased stimulation of B cells to produce antibodies.
Oral vaccination has been described as the ideal vaccination method for fish, but only few vaccines for oral application are licensed. Therefore, the established oral model for vaccination of rainbow trout with attenuated viral hemorrhagic septicemia virus (VHSV) was adapted to be used for inactivated A. salmonicida, even though initial trials indicated great similarities in the cellular response after i.p. and oral vaccination with inactivated strains of A. salmonicida, particularly in the response of the myeloid cells and lymphocytes in the target organs as well as the thrombocytes in the spleen. This could not be confirmed in a second oral vaccination trial. These results show how challenging the development of oral vaccines for fish is. The main challenge is the reproducibility of reliable results, since this is influenced by the difference in uptake of vaccine pellets or antigen degradation in the gut. Future oral vaccine trials should investigate different vaccination regimes, e.g., consecutive feeding, or a different composition of vaccine pellets, in order to further investigate the possibility of establishing an oral vaccine model for trout and so that future vaccine candidates, like OMVs, can be reliably tested in fish.
The role of cell-penetrating peptides in the induction of T cell responses by virus-like particles
(2023)
Many viral structural proteins can self-assemble into virus-like particles (VLPs). VLPs can serve as an effective vaccine or be used as a vaccine platform. One of these structural proteins is the hepatitis B virus core antigen (HBcAg), which appears to be suitable as an antigen carrier due to its high immunogenicity. HBcAg has a major immunodominant region (MIR) that is presented on the surface of the VLPs after self-assembly. Foreign antigens can be inserted into this region. Since HBcAg VLPs, unlike the Hepatitis B virus (HBV), do not have an envelope, they are not able to penetrate cell membranes efficiently. As an extracellular antigen, HBcAg VLPs primarily induce a strong humoral immune response.
In the present study, we investigated the extent to which HBcAg can be modified to also elicit an enhanced cellular, particularly a cytotoxic, immune response. A cytotoxic CD8+ T cell response is predominantly induced by intracellular antigens. Therefore, our goal was to increase the cell penetration capacity of VLPs. We aimed to achieve this by fusing cell-penetrating peptides (CPPs) to HBcAg. CPPs can spontaneously penetrate cell membranes to enter the cytoplasm of cells. To guarantee that the CCPs were localized to the surface of the VLPs, we fused CPPs to the N-terminus of HBcAg. The CCPs were followed by a tag to allow the purification of VLPs. The T cell epitopes, against which the induced CTL should be directed, were derived from the Large T antigen and inserted into the MIR of HBcAg. Finally, we fused fluorescent proteins to the C-terminus of HBcAg to track the entry of VLPs into cells.
Modifications of HBcAg may lead to reduced stability or altered structure of VLPs. To analyze the stability of VLPs, we used nanoscale differential scanning fluorimetry (nanoDSF) analysis. This revealed that the N-terminal fusion of CPPs or the tag to HBcAg does not reduce VLP stability. However, some peptides incorporated into the MIR had a significant effect on the structure and stability of the VLPs. While the incorporation of a Flag-tag or a peptide from ovalbumin had no negative effect on VLP stability, the incorporation of peptides representing T cell epitopes of Large T antigen interfered with VLP formation. Denaturation and reassembly of the aggregates significantly improved the homogeneity of the VLPs, and the C-terminal addition of arginine-rich domains enhanced stability.
Using live cell imaging and flow cytometry, we demonstrated that HBcAg VLPs functionalized with CPP exhibited up to 40% more efficient penetration into professional antigen-presenting cells (JAWS II) than HBcAg VLPs without CPP. This resulted in the increased presentation of integrated T cell epitopes by dendritic cells. In vivo, we detected significantly increased induction of SV40 Large T antigen-specific CTL in mice immunized with CPP-conjugated VLPs compared to unconjugated VLPs.
In this study, we demonstrated that a stronger cellular immune response can be induced by CPP-functionalized HBcAg VLPs than with the unmodified HBcAg VLPs in vitro as well as in vivo. This discovery may have positive implications for future vaccine development where an enhanced cellular component of the immune response is desirable.